PCAS PCAS 8% BONDS DATED- 31/12/2016 BUY BACK
PCAS announces they have repurchased a total of 7 439 PCAS' 8% Bonds dated 31/12/2016 (FR 0010480707) out of the 33 333 bonds issued in 2007, representing approximately 22,3% of the outstanding bonds.
This operation, which will achieve savings in financial charges, fits in the PCAS' financial debt optimization strategy.
PCAS specialises in the development and production of complex molecules for Life Sciences and Innovative Technologies. With 7% of its turnover dedicated to R&D and a wide international presence, PCAS is the preferred industrial partner of market-leading major global groups. The company offers a growing range of proprietary products and solutions in leading- edge segments, and also includes two subsidiaries with very strong potential: Protéus in biotechnology and Enersens in high- performance insulation. With a particularly high standard of performance, PCAS achieved net sales of €179,1 million in 2015 and employs nearly 900 people in six countries.
For more information about PCAS: www.pcas.com
.
PCAS | NewCap |
Vincent Touraille / Eric Moissenot PCAS | Emmanuel Huynh / Louis-Victor Delouvrier NewCap Financial Communication & investors relations |
Tel. : +33 1 69 79 61 32 www.pcas.com | Tel. : +33 1 44 71 98 53 pcas@newcap.eu |
PCAS SA issued this content on 15 February 2016 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 15 February 2016 17:52:10 UTC
Original Document: http://www.pcas.com/content/download/3313/51801/version/3/file/Press release 15th February 2016.pdf
